Practical measurement of total and bioavailable estradiol in female macaques

Clinica Chimica Acta

Volumn 340, Issue 1-2, 2004, Pages 117-126

  Pazol, Karen ^a   Kaplan, Jay R ^b   Abbott, David ^c   Appt, Susan E ^b   Wilson, Mark E ^a  

^a EMORY UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Bioavailable; Estradiol; Immunoassay; Monkey model

Indexed keywords

AMMONIUM SULFATE; ESTRADIOL;

ARTICLE; BIOAVAILABILITY; BLOOD ANALYSIS; CHROMATOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; EXTRACTION; FEMALE; MACACA; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SEX HORMONE DETERMINATION; ULTRAFILTRATION;

MACACA;

EID: 0842324559     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2003.10.010     Document Type: Article

References (53)

1. Merz C.N.B., Johnson B.D., Sharaf B.L.et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J. Am. Coll. Cardiol. 41:2003;413-419.
2. Stampfer M.J., Willett W.C., Colditz G.A., Rosner B., Speizer F.E., Hennekens C.H. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N. Engl. J. Med. 313:1985;1044-1049.
3. Stampfer M.J., Colditz G.A., Willett W.C.et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N. Engl. J. Med. 325:1991;756-762.
4. Barrett-Connor E., Bush T.L. Estrogen and coronary heart disease in women. JAMA. 265:1991;1861-1867.
5. O'Connell D., Robertson J., Henry D., Gillespie W. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women: II. An assessment of treatment effects. Climacteric. 1:1998;112-123.
6. Miller E., Kalin M.F. A review of combination regimens for osteoporosis - prevention and treatment. Int. J. Fertil. Womens Med. 47:2000;198-204.
7. Rapp S.R.P., Espeland M.A.P., Shumaker S.A.P.et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative memory study: a randomized controlled trial. JAMA. 289:2003;2663-2672.
8. Shumaker S.A.P., Legault C.P., Rapp S.R.P.et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative memory study: a randomized controlled trial. JAMA. 289:2003;2651-2662.
9. Waring S.C., Rocca W.A., Petersen R.C., O'Brien P.C., Tangalos E.G., Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology. 52:1999;965-970.
10. Jacobs D.M.P., Tang M.X.P., Stern Y.P.et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology. 50:1998;368-373.
11. Wassertheil-Smoller S.P., Hendrix S.D.O., Limacher M.M.D.et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 289:2003;2673-2684.
12. Colditz G.A., Hankinson S.E., Hunter D.J.et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 332:1995;1589-1593.
13. Magnusson C., Baron J.A., Correia N., Bergstrom R., Adami H.O., Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin- replacement therapy. Int. J. Cancer. 81:1999;339-344.
14. Steinberg K.K., Thacker S.B., Smith S.J.et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 265:1991;1985-1990.
15. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 283:2000;485-491.
16. Gerhardsson de Verdier M., London S. Reproductive factors, exogenous female hormones, and colorectal cancer by subsite. Cancer Causes Control. 3:1992;355-360.
17. Smith D.C., Prentice R., Thompson D.J., Herrmann W.L. Association of exogenous estrogen and endometrial carcinoma. N. Engl. J. Med. 293:1975;1164-1167.
18. Karas R.H., Clarkson T.B. Considerations in interpreting the cardiovascular effects of hormone replacement therapy observed in the WHI: timing is everything. Menopausal Med. 10:2003;8-12.
19. Hotchkiss C.E., Stavisky R., Nowak J., Brommage R., Lees C.J., Kaplan J. Levormeloxifene prevents increased bone turnover and vertebral bone loss following ovariectomy in cynomolgus monkeys. Bone. 29:2001;7-15.
20. Lacreuse A., Verreault M., Herndon J.G. Fluctuations in spatial recognition memory across the menstrual cycle in female rhesus monkeys. Psychoneuroendocrinology. 26:2001;623-639.
21. Cline J.M., Soderqvist G., von Schoultz E., Skoog L., von Schoultz B. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res. Treat. 48:1998;221-229.
22. Bethea C.L., Mirkes S.J., Shively C.A., Adams M.R. Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques. Biol. Psychiatry. 47:2000;562-576.
23. Clarkson T.B., Anthony M.S., Mikkola T.S., St. Clair R.W. Comparison of tibolone and conjugated equine estrogens effects on carotid artery atherosclerosis of postmenopausal monkeys. Stroke. 33:2002;2700-2703.
24. Roy B.N., Reid R.L., Van Vugt D.A. The effects of estrogen and progesterone on corticotropin-releasing hormone and arginine vasopressin messenger ribonucleic acid levels in the paraventricular nucleus and supraoptic nucleus of the rhesus monkey. Endocrinology. 140:1999;2191-2198.
25. Schioler V., Thode J. Six direct radioimmunoassays of estradiol evaluated. Clin. Chem. 34:1988;949-952.
26. Levesque A., Letellier M., Dillon P.W., Grant A. Analytical performance of Bayer Immuno 1 estradiol and progesterone assays. Clin. Chem. 43:1997;1601-1609.
27. Rodriguez-Espinosa J., Otal-Entraigas C., Gascon-Roche N.et al. Analytical and clinical performance of an automated immunoassay system (Immulite) for estradiol in serum. Clin. Chem. Lab. Med. 36:1998;969-974.
28. van den Beld A.W., de Jong F.H., Grobbee D.E., Pols H.A., Lamberts S.W. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J. Clin. Endocrinol. Metab. 85:2000;3276-3282.
29. Kabuto M., Akiba S., Stevens R.G., Neriishi K., Land C.E. A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol. Biomarkers Prev. 9:2000;575-579.
30. Thomas T., Burguera B., Melton I., Melton L.J.et al. Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone. 29:2001;114-120.
31. Szulc P., Munoz F., Claustrat B.et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J. Clin. Endocrinol. Metab. 86:2001;192-199.
32. Yaffe K., Lui L., Grady D., Cauley J., Kramer J., Cummings S.R. Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet. 356:2000;708-712.
33. Laughlin G.A., Barrett-Connor E., Kritz-Silverstein D., von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: The Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 85:2000;645-651.
34. Pardridge W.M. Serum bioavailability of sex steroid hormones. Clin. Endocrinol. Metab. 15:1986;259-278.
35. Ekins R. Free hormone assays. Nucl. Med. Commun. 14:1993;676-688.
36. Vermeulen A., Verdonck L., Kaufman J.M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab. 84:1999;3666-3672.
37. Rosner W. Letter to the editor: An extraordinarily inaccurate assay for free testosterone is still with us. J. Clin. Endocrinol. Metab. 86:2001;2903.
38. Vermeulen A., Kaufman J.M. Diagnosis of hypogonadism in the aging male. Aging Male. 5:2002;170-176.
39. Stanczyk F.Z. Free testosterone in the evaluation of androgen excess. Azziz R., Nestler J.E., Dewailly D. Androgen excess disorders in women. 1997;647-656 Lippincott-Raven Publishers, Philadelphia.
40. French J.A., Abbott D.H., Scheffler G., Robinson J.A., Goy R.W. Cyclic excretion of urinary oestrogens in female tamarins (Saguinus oedipus). J. Reprod. Fertil. 68:1983;177-184.
41. Wilson M.E., Gordon T.P., Rudman C.G., Tanner J.M. Effects of a natural versus artificial environment on the tempo of maturation in female rhesus monkeys. Endocrinology. 123:1988;2653-2661.
42. Koritnik D., Marschke K. Sex steroid hormone binding globulin levels and free 17 beta-estradiol and testosterone in cynomolgus monkeys during different reproductive states. J. Steroid Biochem. 25:1986;135-141.
43. Koritnik D., Marschke K. Contraceptive steroid treatment affects steroid binding proteins and the percentage of free 17 beta-estradiol and testosterone in the cynomolgus monkey (Macaca fascicularis). J. Steroid Biochem. 26:1987;227-234.
44. Cumming D.C., Wall S.R. Non-sex hormone-binding globulin-bound testosterone as a marker for hyperandrogenism. J. Clin. Endocrinol. Metab. 61:1985;873-876.
45. O'Connor S., Baker H.W., Dulmanis A., Hudson B. The measurement of sex steroid binding globulin by differential ammonium sulfate precipitation. J. Steroid Biochem. 4:1973;331-339.
46. Tremblay R.R., Dube J.Y. Plasma concentrations of free and non-TeBG bound testosterone in women on oral contraceptives. Contraception. 10:1974;599-605.
47. Wilson M.E., Gordon T.P., Collins D.C. Variation in ovarian steroids associated with the annual mating period in female rhesus monkeys (Macaca mulatta). Biol. Reprod. 27:1982;530-539.
48. Thienpont L. Meeting report: first and second estradiol International workshops. Clin. Chem. 42:1996;1122-1124.
49. Makela S.K., Ellis G. Nonspecificity of a direct 17 alpha- hydroxyprogesterone radioimmunoassay kit when used with samples from neonates. Clin. Chem. 34:1988;2070-2075.
50. Diver M.J. Monitoring of hormone replacement therapy. Lancet. 340:1992;1471.
51. Diver M.J., Nisbet J.A. Warning on plasma oestradiol measurement. Lancet. 2:1987;1097.
52. Cook N.J., Read G.F. Oestradiol measurement in women on oral hormone replacement therapy: the validity of commercial test kits. Br. J. Biomed. Sci. 52:1995;97-101.
53. Takahashi K., Karino K., Kurioka H.et al. Estradiol-17beta measurement in women receiving conjugated estrogens: dissociation between two commercial methods. Clin. Chim. Acta. 284:1999;69-79.